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Abstract
Mounting evidence indicates that the vagina can harbor uropathogenic
bacteria. Here, we consider three roles played by the vagina and its
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First, the vagina can serve as a reservoir for Escherichia coli, the most
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culture but are underappreciated as uropathogens, and other vaginal
species are likely under-reported because of their fastidious nature.
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and shift the balance of host-pathogen interactions to influence the
outcomes of uropathogenesis. This chapter describes the current liter-
ature in these three areas and summarizes the impact of the vaginal
microbiota on susceptibility to UTI and other urologic conditions.
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Summary of findings
1. Data from clinical studies andmodel systems highlight
the vaginal microbiota as a key factor impacting sus-
ceptibility to UTI and other urologic conditions.
2. The vagina can serve as a reservoir for uropathogen
colonization.
3. Certain members of the vaginal microbiome are fre-
quently detected in urine yet are underappreciated
as uropathogens. Other vaginal bacterial species are
likely underreported because they are difficult to cul-
ture or to identify.
4. The urinary tract can be transiently exposed to vaginal
bacteria, some of which can cause injury to the blad-
der epitheliumand impact pathogenesis of recognized
uropathogens.
1 Introduction
It is well known, that women suffer from urinary tract in-
fections (UTI) muchmore frequently thanmen. Mounting
evidence indicates that the vagina can harbor uropatho-
genic bacteria. According to the current literature we
consider the evidence from clinical correlations and ex-
perimental models that the vaginal microbiota impacts
susceptibility to UTI and other urologic conditions.
2 Methods
We performed literature searches in PubMed. For our
overview of the vaginal microbiome and its impact on the
urinary tract, we searched “vaginal microbiome” OR “va-
ginal microbiota” AND “bacterial vaginosis” OR “BV” OR
“dysbiosis”. To find articles relating to vaginal colonization
by uropathogens, we searched “Escherichia coli” OR
“Staphylococcus” OR “group B Streptococcus” OR “GBS”
AND “vagina” OR “vaginal”. To identify articles relating to
vaginal species that may be underappreciated uropatho-
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Figure 1: Examples of Gram-stained slides from women with (right, Nugent score = 9) and without (left, Nugent score = 1) BV.
In women with a lactobacilli-dominated microbiome (left), long purple rods are the main morphotype. In contrast, women with BV
tend to have a lot more bacteria overall, with a significant fraction that do not stain as Gram-positive (i.e. pink). Morphotypes in
BV tend not to be long Gram-positive rods. Although not part of the Nugent scoring system, women with BV tend to have large
conglomerations of bacteria associated with epithelial cells as seen in the upper right quadrant.
gens, we examined the list of organisms commonly de-
tected in vaginal microbiome studies and searched these
organisms along with “urinary tract” OR “urine” OR “UTI”.
3 Results and discussion
In order to better understand the role of the vaginal mi-
crobiota in UTI, we consider the “healthy” or “normal”
state in reproductive age women and in pregnancy and
three roles played by the bacterial inhabitants of the va-
gina in UTI and urinary health. First, the vagina can serve
as a reservoir for Escherichia coli, the most common
cause of UTI, and other recognized uropathogens. Second,
several vaginal bacterial species are frequently detected
upon urine culture but are underappreciated as uropatho-
gens, and other vaginal species are likely under-reported
because of their fastidious nature. Third, some vaginal
bacteria that are not widely viewed as uropathogens can
transit briefly in the urinary tract, cause injury or immuno-
modulation, and shift the balance of host-pathogen inter-
actions to influence the outcomes of uropathogenesis.
3.1 Vaginal microbiota composition
In reproductive age women, the vaginal microbiota is
dominated by a few Lactobacillus species, including
L. crispatus, L. gasseri, L. jensenii, and L. iners. These
lactobacilli are thought to prevent growth of potential
pathogens by maintaining the vagina’s characteristic low
pH (by producing lactic acid [1]) and by producing antimi-
crobials such as hydrogen peroxide and bacteriocin-like
substances [2]. Although a Lactobacillus-dominant vaginal
microbiota is considered the “healthy” or “normal” state,
a large proportion of reproductive age women (up to one-
third in the United States) have a more diverse vaginal
microbiota that contains no or low levels of Lactobacillus
and a mixture of Gram-negative anaerobes, Actinobac-
teria, and other Firmicutes [3]. This apparent dysbiosis
is called bacterial vaginosis (BV) or community state type
IV [4]. While fewer studies have examined postmenopaus-
al women, these echo what has been observed in
younger cohorts, with some women having Lactobacil-
lus-dominant and others having a more diverse polymi-
crobial vaginal microbiome [5], [6], [7]. A few studies have
suggested that pregnancy may favor a stable Lactobacil-
lus-dominant vaginal microbiome, however, a diverse
vaginal microbiome is nonetheless present in some
pregnant women [8]. In the clinic, a woman is diagnosed
with BV if she has three of the four following signs (Amsel
criteria): vaginal pH>4.5, ‘thin’ grayish homogenous va-
ginal fluid, vaginal fluid that produces a fishy odor when
treated with potassium hydroxide, and the presence of
epithelial cells studded with bacteria (i.e., ‘clue-cells’) in
wet mount. In the laboratory, BV is diagnosed via the
Nugent scoring system [9], which is based onmorphotype
assessment of Gram-stained slides; a score of 7 or higher
on a 10-point scale indicates BV (see Figure 1 for ex-
amples of Gram-stained slides from women with and
without BV). Women with BV are at higher risk of experi-
encing a wide array of negative health outcomes, includ-
ing increased risk of a variety of secondary infections and
adverse pregnancy outcomes.
3.2 Relationships between the vaginal
microbiota, UTI, and urinary health
Data frommultiple clinical studies suggest that a woman’s
vaginal microbiota affects her susceptibility to UTI [10].
For example, women with BV have higher UTI risk than
women with lactobacilli-dominated vaginal microbiota
[11], [12], [13]. Furthermore, clinical trials suggest that
vaginal interventions that affect the microbiota (e.g., va-
ginal probiotic and estrogen treatments) can protect
against additional episodes of recurrent UTI (rUTI) [14],
[15]. As described later in this chapter, many of the bac-
terial genera found in the BV-associated vaginal environ-
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ment have been detected, via both culture-dependent
and -independent methods, in the urinary tract. Addition-
ally, some of these bacteria have been implicated as
causes of acute UTI or other urologic conditions. These
findings suggest that fastidious BV-associated organisms
may be important in the etiology of uropathology and
uropathogenesis; however, in many cases additional
studies are needed to ascribe causal roles for these or-
ganisms in the urinary tract.
Why women with a disrupted vaginal microbiota are at
increased risk of UTI is unclear. Below, we describe three
ways the vaginal microbiota could influence UTI and other
urologic conditions. First, the vaginal introitus appears to
be a key reservoir for uropathogenic E. coli. Second, other
somewhat less common uropathogens can also be com-
monly harbored in the vagina (see Figure 2). Finally,
transient exposures of the urinary tract to certain vaginal
bacteria may prime the urinary tract for uropathogens or
trigger rUTI via other mechanisms.
Figure 2: Schematic illustrating vaginal bacteria with potential
to impact the urinary tract.
The vagina can serve as a reservoir for several bacterial species
known to be causes of UTI (E. coli, GBS, Staphylococcus) as
well as underappreciated potential uropathogens (G. vaginalis,
Aerococcs Ureaplasma) that can cause UTI and have been
associated with urological conditions such as urgency
incontinence and “sterile” pyuria.
3.3 The vagina provides a reservoir for
uropathogenic E. coli and other
recognized uropathogens
3.3.1 E. coli
The most common cause of UTI in most patient popula-
tions is uropathogenic E. coli [16], [17]. The pathogenesis
of E. coli UTI is often described as a series of colonization
events, starting in the gastrointestinal tract, followed by
the vaginal introitus and urethral meatus, and finally the
bladder and possibly kidneys [10], [18]. This progression
makes sense given the proximity of the urethra to the
vaginal introitus and anus in females and that longitudinal
examinations have indicated that introital and urethral
colonization precedes UTI symptom onset [19], [20].
Moreover, multiple clinical studies have found that women
with a history of rUTI more commonly have E. coli in the
vaginal introitus or vagina than do healthy controls [19],
[20], [21], [22]. One such study found that E. coli coloni-
zation of the vaginal introitus reached higher levels in
women with a history of UTI (>105 colony forming
units/mL) than in controls (<200 cfu/mL) [20]. In a sep-
arate study, concurrent colonization of the vaginal introi-
tus and urinary tract by the same strain of E. coli (based
on random amplified polymorphic DNA fingerprinting)
occurred in 85% of paired isolates from women with a
history of rUTI [20]. Together, these results demonstrate
that the vagina provides a reservoir for uropathogenic
E. coli.
As described above, Lactobacillus in the vagina may
prevent colonization by potential pathogens such as
E. coli. Indeed, women with low levels of lactobacilli more
commonly carry vaginal E. coli than do those with lacto-
bacilli-dominated microbiomes [13], [21]. In one study,
E. coli vaginal (introital) colonization was more common
among women whose vaginal introitus was negative for
hydrogen peroxide-forming lactobacilli than among those
whose introitus was positive for these ‘beneficial’ bacteria
(35% vs. 11%, odds ratio [OR], 4.0; P=0.01) [21]. Multiple
studies in both nonpregnant and pregnantwomen suggest
that those with BV have increased risk for UTI (odds ratios
from 2.21 to 13.75) [12], [23], [24]. In one study, BV was
associated with both E. coli introital colonization and UTI
[13]. In another study, over 50% of women with a history
of UTI, but only 13% of those with no UTI history, had ab-
normal vaginal microbiota (P=0.03) as defined by a Nu-
gent score greater than 3 (mean 4.6 vs. 1.7). Having a
Nugent score of 7 or greater (indicative of BV) was also
more common in UTI-prone women (6/22 [27%] vs. 1/17
[6%], P=0.095) [25]. This may be because lactic acid,
hydrogen peroxide, and other small molecules produced
by lactobacilli create a hostile environment for potential
pathogens, including uropathogens, in the vagina [26].
Additional studies in experimental models are needed to
define the effects of specific small molecules on the va-
ginal environment.
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One intervention that appears to restore Lactobacillus
colonization and may protect against rUTI in some pa-
tients is vaginal probiotics. A double-blind placebo-con-
trolled trial studied 100 premenopausal women with at
least one UTI in the past 12 months. Women received
either intravaginal suppositories of powdered L. crispatus
(Lactin-V) once daily for 5 days and then weekly for
10 weeks or placebo suppositories at the same interval.
Fewer women who established high-level vaginal
L. crispatus colonization (≥106 throughout follow-up) de-
veloped rUTI (relative risks were 0.07 for Lactin-V and
1.1 for placebo; P<0.01) [14]. In contrast, a smaller study
found that vaginal application of other types of lactobacilli
(L. casei and L. rhamnosus) twice weekly did not reduce
the UTI incidence [27]. However, the latter study used a
higher E. coli threshold (104 vs. 102) to diagnose an rUTI.
Additionally, L. casei and L. rhamnosus, which are more
common in the intestine than in the vagina, failed to col-
onize the vagina [27]. Future studies are needed to de-
velop effective vaginal prebiotic and probiotic strategies
to treat or prevent rUTI.
Another promising intervention is vaginal estrogen. This
idea is based on the observation that high levels of vagi-
nal lactobacilli occur only in 25% to 30% of postmeno-
pausal women (who tend to have low estrogen levels) but
in 60% to 70% of women who receive estrogen replace-
ment therapy. In a placebo-controlled study of postmeno-
pausal womenwith rUTI, vaginal estrogen restored vaginal
Lactobacillus colonization and decreased vaginal En-
terobacteriaceae colonization (67% of women pre-treat-
ment vs. 31% post-treatment). Moreover, the UTI inci-
dence was lower in the estrogen group than in the
placebo group (0.5 vs. 5.9 episodes per patient year;
P<0.001) [15]. In a separate study, women receiving va-
ginal estrogen had a 45% cumulative likelihood of remain-
ing UTI-free over a 36-week follow up period, whereas
those in the control group had only 20% likelihood of re-
maining UTI-free [28]. For a more detailed description of
the clinical studies examining the role of Lactobacillus
and E. coli vaginal colonization and vaginal interventions
for UTI, please see this recent review [10].
3.3.2 Staphylococcus
The most frequent Gram-positive agent of community-
acquired UTI is S. saprophyticus, but S. aureus and
S. epidermidis can also cause UTI in certain settings
(catheterization, pregnancy) [29], [30], [31]. Staphylococ-
cus uropathogenesis was recently reviewed [32]. Data
from in vitro studies and rat UTI models have revealed
several factors required for S. saprophyticus virulence,
including the secreted surface-associated proteins Aas
(hemagglutinin) and Ssp (lipase); the cell wall proteins
UafA, SdrI, SssF, and UafB, which mediate adherence;
and a urease that is associated with urinary stone form-
ation. Additionally, data from amousemodel suggest that
the nickel ABC-transporters Opp2 and Opp5a contribute
to S. aureus uropathogenesis.
Both S. aureus and S. epidermidis have been detected
in vaginal or cervical samples [33], [34], [35]. Vaginal
S. aureus has been implicated in toxic shock syndrome
and aerobic vaginitis [36], [37], [38], a controversial in-
flammatory condition often mistaken for BV or Candida
yeast infection. One study found that women with vaginal
toxicogenic S. aureus were significantly more likely than
those without S. aureus to harbor vaginal E. coli [38].
However, vaginal colonization by staphylococci has not
been examined as a risk factor for UTI.
3.3.3 Group B Streptococcus
Streptococcus agalactiae, otherwise known as group B
Streptococcus (GBS), is a Gram-positive β-hemolytic chain-
forming coccus that commonly inhabits the lower
gastrointestinal tract and the vagina. Although GBS col-
onization is often asymptomatic, GBS has been implicated
in aerobic vaginitis [39]. GBS is also a recognized uro-
pathogen, causing 2–3% (or ~160,000 cases annually
in the U.S.) of all uncomplicated UTIs [17], [40]. GBS UTIs
are more common in certain vulnerable populations. For
example, among nursing home residents over 70 years
of age, up to 39% of UTI cases involve GBS [41]. Addition-
ally, GBS often causes asymptomatic bacteriuria and is
found at significant titers in up to 7% of pregnant women
[42], [43]. GBS is also frequently found in the urinary
tract of people with diabetes, immunocompromised indi-
viduals, and thosewith pre-existing urologic abnormalities,
all of whom are at increased risk of ascending pyeloneph-
ritis that can progress to bacteremia and/or urosepsis
[44], [45]. Although GBS can inhabit both the vagina and
the urinary tract, no studies have assessed the associ-
ation between vaginal GBS and GBS UTI.
Mouse models of GBS UTI [46], [47], [48], [49] have
mainly used serotype III GBS strains, which cause more
symptomatic UTIs than most other serotypes [45]. The
role of GBS virulence factors has not been as thoroughly
examined in the urinary tract as in other niches, such as
the bloodstream. However, available data suggest that
the β-hemolysin/cytolysin is dispensable, whereas sialic
acid residues of the GBS capsular polysaccharide are
important for GBS survival in the urinary tract [47], [48].
Further studies are needed to define the bacterial and
host mechanisms governing GBS disease in the urinary
tract.
3.4 Other vaginal bacterial species that
are underappreciated as uropathogens
3.4.1 Gardnerella vaginalis
Gardnerella vaginalis, a facultative Gram-variable
Actinobacteria (a class frequently called ‘high-GC Gram-
positives’), is best known as a frequent isolate and dom-
inant member of the vaginal microbiota in BV. Although
G. vaginalis is considered an unusual primary pathogen
of the urinary tract, this bacterium can cause acute UTI
[50]. The contribution of G. vaginalis to urinary tract
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pathology is likely underestimated for two reasons. First,
G. vaginalis does not grow under the standard (aerobic)
culture conditions that most clinical microbiology labs
use. Second, when labs identify G. vaginalis in urine cul-
tures, they do not report it as a potential uropathogen
(even if present in pure culture at levels exceeding clinical
thresholds for UTI diagnosis). Several studies suggest
that G. vaginalis should be considered as a potential
cause of urinary tract pathology. For example, in one study
using appropriate culture conditions to detect it, G. va-
ginaliswas isolated from 2.3% of urines from hospitalized
patients, often in pure culture and >10,000 colony
forming units per milliliter (cfu/ml). Compared to individu-
als in whom G. vaginalis was not detected, patients with
G. vaginalis bacteriuria were more likely to have a history
of rUTI or current pyelonephritis (kidney infection) [51].
These patients often reported symptoms, and 58% had
pyuria (neutrophils in urine) [51]. Another study showed
that the frequency of G. vaginalis in catheterized urine
samples was higher in womenwith urgency urinary incon-
tinence than in women with other urologic conditions
[52]. Other studies have used suprapubic needle aspira-
tion to collect urine from the bladder, bypassing possible
vaginal contaminants, concluding that pregnancy in-
creases women’s risk of harboring G. vaginalis in their
bladders and that G. vaginalis was especially common in
women with underlying renal disease [53], [54], [55],
[56], [57]. In another study, G. vaginalis was commonly
found in suprapubic aspirates from women with reflux
scarring and “sterile pyelonephritis” [58]. Bladder
washout studies strongly suggested thatG. vaginaliswas
present in the kidneys of 75% of these patients. Finally,
case reports implicate G. vaginalis in more serious dis-
eases. For example, G. vaginalis has been isolated from
women's bloodstreams during or after giving birth [59],
and G. vaginalis bacteremia has been implicated in sys-
temic diseases coinciding with urolithiasis (kidney stones)
[60]. In short, G. vaginalis has been implicated in rUTI,
urgency incontinence, kidney disease, and systemic infec-
tions originating in the genitourinary system.
Thus far, few reports have assessed G. vaginalis in both
the vagina and the urinary tract. However, one recent
study compared themicrobiota of pairedmidstreamurine
and vaginal fluid from 42 women with BV [61] and found
high levels of G. vaginalis in urine in a subset of women.
The authors noted an association between urine and va-
ginal fluid communities in ~60% of women with urotypes
dominated by G. vaginalis, Prevotella amni, Atopobium
vaginae, or Sneathia amnii. In contrast, they reported
only a 10–30% correlation among other urotypes (E. coli,
Lactobacillus, etc.). The authors state that urine and va-
ginal microbiota patterns were not correlated in most
women, and suggest that the two communities are
therefore distinct in many women. However, despite the
suggestion that some vaginal bacteria, including G. va-
ginalis, can exist concurrently in the vagina and urinary
tract, this manuscript does not appear to have evaluated
the co-occurrence of individual taxa per se in the two
different compartments. The findings raise a number of
interesting questions, including whether vaginal coloniza-
tion with G. vaginalis a risk factor for G. vaginalis in urine
or having concurrent or subsequent urologic pathologies.
G. vaginalis isolates have highly diverse genomes and
can be divided into at least four clades. In fact, some
authors have suggested that G. vaginalis should be di-
vided into multiple species or even genera [62], raising
the question of whether certainG. vaginalis subtypes are
more likely to be pathogenic in the urinary tract.
3.4.2 Aerococcus
Aerococcus is an α-hemolytic and microaerophilic or
facultatively anaerobic Gram-positive coccus. Several
Aerococcus species, including A. urinae, A. viridans, and
A. sanguinicola, can cause UTI and urosepsis [63], [64],
[65], [66], [67], [68], [69]. Patients with Aerococcus UTI
often have underlying risk factors, such as urological ab-
normalities or older age [66], [67], [70]. Many case re-
ports describing significant Aerococcus titers in urine also
reported isolating the bacterium from blood [66], [71],
[72]. Aerococcusmust be properly identified and treated
to avoid life-threatening systemic infection [68]. However,
Aerococcus is difficult to distinguish from viridans-group
streptococci with routine phenotypic tests and thus re-
quires molecular tools such as amplification and
16S rRNA sequencing, amethod not commonly employed
in clinical microbiology labs. Additionally, most reported
Aerococcus isolates are resistant to sulfonamides [69],
[70]. Thus, when Aerococcus is not recognized, ineffective
antibiotic treatment can be given, leading to rapid pro-
gression to systemic infection [67], [69], [71], [72], [73].
In addition to being implicated in UTI, Aerococcus was
more frequently cultured from urine (collected by
transurethral catheterization) from patients with urgency
urinary incontinence than fromwomenwith other urinary
tract conditions [52]. To our knowledge, Aerococcus
pathogenesis in the urinary tract has not been examined
with in vivo models.
Aerococcus sp. are commonly isolated from the human
vagina and urinary tract and from air, dust, and vegeta-
tion. More studies are needed to understand how these
natural Aerococcus niches affect pathogenesis and the
clinical course of infections [74]. Aerococcus vaginal
colonization is more common and abundant in women
with BV [75], [76], but no studies have examinedwhether
womenwith BV, or their sexual partners, are at increased
risk for Aerococcus UTI.
3.4.3 Ureaplasma
Ureaplasma species, including U. urealyticum and
U. parvum, are characterized by their ability to hydrolyze
urea. U. parvum UTI pathogenesis was examined in
Fischer 344 rats, revealing two distinct outcomes. Some
animals developed a minimal immune response with
limited monocytic and lymphocytic lesions and elevated
urinary interferon (IFN)-γ, interleukin (IL)-18, and mono-
cyte chemoattractant protein-1. Other animals developed
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an exaggerated pro-inflammatory immune response with
elevated urinary IL-1α, IL-1β, CXCL1 (a.k.a. KC), neutro-
philic lesions with extensive uroepithelial hyperplasia,
and struvite (stone) formation [77]. A separate study
demonstrated that rat strains differed in their susceptibil-
ity to U. parvum UTI and struvite formation [78]. Together,
these studies suggest that host factors influence U. par-
vum UTI outcomes.
Between 40% and 80% of sexually active women have
vaginal/cervical ureaplasmas [79]. Some studies indicate
that Ureaplasma vaginal colonization increases during
BV, but others have failed to find associations with BV
[80] or vaginal symptoms in general [81]. However, ur-
eaplasmas are reproducibly the most common cause of
amniotic fluid infection in pregnant women, suggesting
the bacteria can invade urogenital tissues and cause
serious infection [82], [83]. Although acute cystitis by
Ureaplasma is rare, the genus has been implicated in
lower urinary tract symptoms [84], [85], including over-
active bladder [86], “sterile pyuria” [87], and unexplained
chronic voiding symptoms [85]. Further studies are
needed to determine whether vaginal Ureaplasma is a
risk factor for UTI or other lower urinary tract symptoms.
3.5 Covert pathogenesis
Although many consider the bladder to be sterile in the
absence of UTI, clinical microbiology laboratories often
find that urines have “insignificant” titers of bacteria (the
“significant” threshold is usually ~100,000 cfu/ml). Addi-
tionally, numerous reports have described the composi-
tion of bacteria in urine (the urinary microbiome), further
suggesting that bacteria can exist, at least transiently, in
the urinary tract. The urinary microbiome is covered in
greater detail elsewhere. Here, it is relevant to note that
many of these studies have detected bacterial genera
that have been independently found as part of the vaginal
microbiota, including Lactobacillus, Streptococcus, and
the BV-associated organisms Gardnerella, Prevotella,
Bacteroides, and others [88]. Several studies classified
urine samples into “urotypes” based on the dominant
organisms, L. crispatus and G. vaginalis often being the
most frequent [52]. Although the presence of these bac-
teria in urine is often attributed to contamination of urine
by vaginal fluid, several studies have identified Gardner-
ella and lactobacilli in urine collected by transurethral
catheterization or suprapubic aspiration, which completely
rules out the possibility of contamination by periurethral
or vaginal bacteria [89].
Vaginal bacteria can enter the urinary tract bymechanical
transfer from nearby sites [10], [18], such as during
sexual activity. In support of this idea, sexual activity (and
its frequency) is one of the strongest risk factors for UTI
and rUTI [15], [16], [90], [91], [92], [93], [94]. In addition
to uropathogens such as E. coli, sexual activity likely also
transfers numerous other vaginal bacteria. This possibility
points to a new idea: that transient urinary tract exposure
to certain vaginal bacteria can directly influence UTI
pathophysiology even if these vaginal bacteria do not
colonize the bladder or are cleared by the host before UTI
diagnosis. This idea has been referred to as “covert
pathogenesis” and is supported by findings from mouse
models in which the urinary tract was exposed to different
common vaginal bacteria within the context of E. coli UTI.
For example, in one model, mice were exposed to group
B Streptococcus (GBS, see above), a known immunomod-
ulatory bacterium during acute or chronic bladder lumen
infection by E. coli in C3H/HeN mice. The studies
demonstrated that the presence of GBS enhanced E. coli
survival in the bladder lumen in the early hours of acute
infection, despite the fact that GBS was more rapidly
cleared by the host during E. coli infection. In fact, even
attenuated strains of E.c. lacking the ability to adhere to
the bladder epithelium due tomutation of the type I pilus,
had higher E. coli bladder lumen titers when GBS was
present [11]. The presence of GBS also had effects on
E. coli infection during chronic inflammatory infection of
the bladder lumen by E. coli. This study provided an initial
proof of principle that the composition of bacterial expo-
sures to the urinary tract (containing E. coli) may influence
initial host-E. coli interactions and therefore help deter-
mine whether E. coli causes UTI.
In another model, effects of another vaginal bacterium
were studied during latent E. coli infection within intracel-
lular epithelial reservoirs in C57/Bl6 mice (from a previ-
ous experimental infection), to investigate possible trig-
gers of recurrent E. coli UTI arising from such reservoirs
[95]. In these mice, two exposures to G. vaginalis
triggered E. coli emergence into the bladder lumen, result-
ing in rUTI.G. vaginalis exposure also increased the incid-
ence of severe E. coli kidney infections. G. vaginalis
caused these effects despite being rapidly cleared from
the urinary tract (by 12 hours in most mice). Even in the
absence of latent E. coli (but also in the rUTI model),
G. vaginalis caused apoptosis and exfoliation of the
bladder epithelium (see Figure 3) and also caused kidney
damage by an IL-1-receptor-mediatedmechanism. These
findings suggest that G. vaginalis could be an important
trigger of rUTI and a risk factor for pyelonephritis in wo-
men. If data from clinical studies support this idea, then
new treatment options (antibiotics to limit G. vaginalis
colonization) could be tested to help prevent rUTI, espe-
cially among patients with BV.
4 Further research
Wehave describedmultiplemechanisms by which vaginal
bacteria can impact UTI incidence or pathogenesis. Vagi-
nal interventions, whether to eliminate the uropathogen
reservoir or to treat associated vaginal conditions (e.g.,
BV), should be investigated as means to improve UTI
outcomes, particularly in patients with rUTI for whom
chronic antibiotic treatment is the only other option.
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Figure 3: Gardnerella vaginalis induces apoptosis (A) and
exfoliation (B) of the mouse bladder epithelium following two
transurethral exposures, using our previously reported model
[95].
Our blinded observation showed that ~75% of animals exposed
to Gardnerella (compared to only ~25% of controls) exhibited
staining for cleaved caspase-3, amarker of apoptotic cell death,
in the outermost epithelium (A, left). Membranous protrusions
were another feature we observed by scanning electron
microscopy that is consistent with apoptosis (A, right). We also
observed that G. vaginalis triggers exfoliation of superficial
umbrella cells, revealing smaller underlying cells of the
transitional epithelium (B). Scale bars = 20 μm.
5 Conclusions
Although E. coli is unquestionably the dominant cause of
UTI in young, sexually active women, it is clear that UTI
and recurrent UTI stem from a wide array of etiologies.
As outlined here, vaginal bacteria may cause UTI, either
themselves (i.e. a traditional uropathogen using the va-
gina as a reservoir) or by acting as a “covert pathogens”
to facilitate pathogenesis of another organism. Clinical
microbiology labs commonly designate vaginal bacteria
– whether identified in pure culture or detected alongside
an accepted uropathogen that is present at levels above
the usual clinical threshold for UTI – as being of “ques-
tionable clinical significance”. We emphasize that, rather
than meaning that vaginal bacteria in urine are not im-
portant, this simplymeans that we do not fully understand
their effects. UTI caused or encouraged by vaginal bac-
teria represent significant etiologies that should not be
overlooked, as evidenced by findings that vaginal inter-
ventions to increase lactobacilli colonization have prom-
ising effects in certain patient subsets, as well as experi-
mental models showing that certain vaginal bacteria can
be “covert pathogens” (i.e. encourage virulence by recog-
nized uropathogens despite their own rapid clearance).
Note
This article is also to be published as a chapter of the
Living Handbook “Urogenital Infections and Inflamma-
tions“ [96].
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